MSM PROTEIN TECHNOLOGIES, INC

WOBURN, MA · CIK 0001560315 · Biotech · Private

Human monoclonal antibodies targeting GPCRs and integral membrane proteins for therapeutic development

msmprotein.com →
Grants
$158K
1 award
Sector median: 1
Raised
$250K
1 Form D · Oct 2012
168 months since last filing
Contracts
—
No federal contracts on record
Patents
2
0 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$250,000
Federal grantDepartment of Health and Human Services · Phase I · CCR7-Depleted Allogeneic Peripheral Blood Stem Cell Product Retaining Effector Memory T Cells for Hematopoietic Transplantation$157,616
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2619Repertoire Immune Medicines——
2620KarnaTeq, Inc.—$250K
2621ROME Therapeutics——
2622MSM PROTEIN TECHNOLOGIES, INC—$250K
2623SNC THERAPEUTICS, INC.—$250K
2624Dome Therapeutics, LLC—$250K
2625X1 Biotech Inc.—$235K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 4 related persons
  • C. FarmerDirector · Executive Officer
  • Christopher HentschelDirector
  • Eldar KimDirector · Executive Officer
  • David KreimerDirector · Executive Officer

Patents

USPTO · 0 granted of 2
  • ANTI-CXCR4 Antibodiesapplication
  • ANTI-CXCR4 Antibodiesapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.